OR WAIT null SECS
CIT announces today a new range of services to meet the growing needs of companies developing the drugs of tomorrow. The services, grouped under the name LeadScreen (TM), offer an array of tests designed to give an early evaluation of safety of drugs thought to have development potential.
Currently, around 20 per cent of candidate drugs fail during standard regulatory non-clinical studies, too often due to late identification of toxicological effects. Using CIT’s LeadScreen (TM), the early detection of potential toxicity can increase the chances of success when the candidate drug goes through the later stages of non-clinical development. LeadScreen (TM) offers the ability to reduce the financial cost and time associated with standard drug development practices.